Market Place
Sourcing Support
Duchenne Innovation Thrives For Real Progress
21 Apr 2026 //
BIOSPACE
Sarepta Eyes FDA Nod for Duchenne Exon Skippers Despite Trial
19 Mar 2026 //
BIOSPACE
Sarepta to Present Gene Therapy, Exon-Skipping Data at MDA 2026
26 Feb 2026 //
BUSINESSWIRE
Sarepta Therapeutics Launches ELEVIDYS In Japan
24 Feb 2026 //
PHARMIWEB
Sarepta Challenges Prompt Search For Advancements In DMD Therapy
09 Feb 2026 //
BIOSPACE
Sarepta Saga Has `Gone On Too Long` As Competitors Catch Up
05 Feb 2026 //
BIOSPACE
Sarepta Secures CTA for SRP-1005 Trial in Huntington`s Disease
04 Feb 2026 //
PHARMIWEB
Sarepta`s DMD Gene Therapy Delays Disease 3 Years Post-Treatment
26 Jan 2026 //
BIOSPACE
Sarepta To Release 3-Year EMBARK Study Data On ELEVIDYS Gene
23 Jan 2026 //
BUSINESSWIRE
Sarepta Submits CTA for SRP-1005 in Huntington`s Disease
07 Jan 2026 //
BUSINESSWIRE
Dyne readies FDA push after DMD exon 51 med excels in trial
08 Dec 2025 //
FIERCE BIOTECH
Sarepta Updates SRP-1003 for Type 1 Myotonic Dystrophy
24 Nov 2025 //
BUSINESSWIRE
FDA Narrows Elevidys Duchenne Gene Therapy Patient Pool
14 Nov 2025 //
FDA
Sarepta, Despite Key Trial Flop, Will Seek Full Nod For DMD Meds
04 Nov 2025 //
FIERCE PHARMA
Sarepta To Unveil Neuromuscular Portfolio Data At 2025 Congress
03 Oct 2025 //
BUSINESSWIRE
Doctors Continue Sarepta’s DMD Gene Therapy Despite Safety Issues
16 Sep 2025 //
BIOSPACE
Sarepta Extends $700M Debt to 2030 Amid Elevidys Uncertainty
21 Aug 2025 //
FIERCE BIOTECH
Sarepta Reveals Restructuring Plan and ELEVIDYS Label Update
16 Jul 2025 //
BUSINESSWIRE
Sarepta Updates ELEVIDYS Safety for Non-Ambulatory DMD
16 Jun 2025 //
BUSINESSWIRE
Sarepta Updates UK Dosing in Elevidys Study for DMD
21 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics` Elevidys Gene Therapy Approved in Japan
13 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics Updates Limb-Girdle Muscular Dystrophy Programs
15 Apr 2025 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
31 Mar 2025 //
BUSINESSWIRE
Sarepta Announces Q4, Full-Year 2024 Results & Developments
26 Feb 2025 //
BUSINESSWIRE
Sarepta Announces Inaugural $600 M Senior Secured Credit Facility
14 Feb 2025 //
BUSINESSWIRE
Sarepta`s Embark Study Part 2 Shows Elevidys Benefits In DMD
27 Jan 2025 //
BUSINESSWIRE
Sarepta Appoints Deirdre Connelly To Board
16 Sep 2024 //
BUSINESSWIRE
US FDA approves expanded use of Sarepta`s Duchenne gene therapy; shares jump
21 Jun 2024 //
REUTERS
Sarepta Therapeutics Announces Recipients of Inaugural LGMD Grant Awards
26 Oct 2022 //
PRESS RELEASE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Jun 2021 //
GLOBENEWSWIRE
New rare disease gene therapy startup recruits former Sarepta executive as CEO
22 Oct 2020 //
STATNEWS
Sarepta inks deal to bolster gene therapy manufacturing
03 Jan 2019 //
BIOPHARMA DIVE
